ClinicalTrials.gg
Not yet recruitingNCT07801547Updated Sep 3, 2026

Muscle Oxygenation in Patients With COPD Exacerbation

An observational study in COPD (Chronic Obstructive Pulmonary Disease), Acute Exacerbation Chronic Obstructive Pulmonary Disease and Muscle Oxygenation, sponsored by Hacettepe University. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by Hacettepe University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
40
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Pulmonary Disease, Chronic Obstructive by Hacettepe University — 10 open to participants now, 12 under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · Hacettepe University.

Planned enrollment
8th of 12
40 · median 45
Started
2026
with 2 others
Observational
12 of 18
8 open now
Primary completion
2027-10
later than 11 of 11 live
Registered
18th of 18
by date

Among the 18 studies in Pulmonary Disease, Chronic Obstructive by Hacettepe University, this one is the 8th largest by planned enrollment of the 12 observational ones that give a count, is one of 3 that started in 2026, is one of 12 observational ones, reaches primary completion later than 11 of the 11 other live ones, and was the 18th registered.

Pulmonary Disease, Chronic Obstructive

5,528 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

10 of the 18 studies in Pulmonary Disease, Chronic Obstructive by Hacettepe University are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Pulmonary Disease, Chronic Obstructive by Hacettepe University, or all of them as a file.
02

Study summary

Chronic obstructive pulmonary disease (COPD) is often complicated by acute exacerbations, which lead to functional impairments, increased dyspnea, and a rapid decline in lung function. During an exacerbation, impaired pulmonary gas exchange, systemic inflammation, and increased work of breathing significantly alter oxygen availability and metabolic demand in skeletal muscles. The aim of this study is to evaluate and compare respiratory and peripheral muscle oxygenation in patients with acute exacerbation of COPD (AECOPD) and patients with clinically stable COPD. By examining these physiological changes, the study seeks to determine the impact of exacerbations on muscle function and oxygenation efficiency

Read the detailed description

Chronic obstructive pulmonary disease (COPD) is characterized by recurrent acute exacerbations that negatively affect patients' quality of life and accelerate lung function decline. Severe exacerbations requiring hospitalization pose a significant mortality risk both during admission and in the following year.

During acute exacerbations, maximal pressure generation by respiratory muscles declines, and respiratory muscle efficiency-particularly of the diaphragm-is significantly reduced. Acute dynamic hyperinflation further shortens the inspiratory muscles, leading to functional muscle weakness. Consequently, accessory respiratory muscles are recruited maximally, often causing notable alterations in chest-wall and abdominal kinematics. Due to the requirement of spending a higher proportion of their maximum capacity with each breath, these patients face an elevated risk of developing respiratory muscle fatigue. Exacerbations lead to severe hypoxemia caused by impaired pulmonary gas exchange, driven primarily by ventilation-perfusion mismatch and increased tissue oxygen consumption. Acute hypoxemia exacerbates muscle weakness and impairs skeletal muscle function. Even after discharge from respiratory intensive care units following severe exacerbations, persistent respiratory muscle dysfunction is observed in more than a third of patients, requiring additional care and rehabilitation.

Physiological factors such as impaired gas exchange, reduced perfusion, and systemic inflammation during exacerbations substantially impact muscle oxygenation. Reduced arterial oxygen content diminishes oxygen availability to peripheral tissues and muscles. Simultaneously, the metabolic demands of both respiratory and peripheral muscles increase due to the heightened work of breathing and systemic stress.

This study aims to investigate respiratory and peripheral muscle oxygenation in patients with AECOPD and stable COPD, evaluating underlying physiological changes and assessing the impact of exacerbations on muscle function and oxygenation dynamics.

The aim of study is to investigate respiratory and peripheral muscle oxygenation in patients with AECOPD.

03

Conditions studied

  • COPD (Chronic Obstructive Pulmonary Disease)
  • Acute Exacerbation Chronic Obstructive Pulmonary Disease
  • Muscle Oxygenation
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consists of adult patients aged 40 years and older diagnosed with Chronic Obstructive Pulmonary Disease (COPD) according to GOLD guidelines. The sample includes two distinct cohorts: patients admitted or presenting with an acute exacerbation of COPD (AECOPD), and patients in a clinically stable period (GOLD Grades 1-4) without exacerbations in the preceding 4 weeks.

Eligibility criteria

Inclusion Criteria:

Acute Exacerbation Group: 1. Diagnosis of (COPD) 2. Hospital admission or presentation due to an acute exacerbation of COPD 3. Age 40 years or older 4. Voluntary agreement to participate with signed written Clinically Stable Group: 1. Diagnosis of COPD (GOLD Stage 1, 2, 3, or 4) 2. Age 40 years or older 3. Clinically stable condition for at least the past 4 weeks without acute exacerbations 4. Voluntary agreement to participate with signed written informed consent

Exclusion Criteria: Acute Exacerbation Group: 1. Active participation in a formal pulmonary rehabilitation program 2. Co-existing neurological disorders 3. Heart failure classified as (NYHA) Class III or IV 4. Unstable mental or cognitive status ( [MMSE] score ≤24) 5. History of surgical intervention within the past three months 6. Presence of malignant conditions .

Clinically Stable Group: 1. History of lung cancer, sarcoidosis, tuberculosis, and/or prior lung surgery 2. Known mental or cognitive impairment.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
40 participants (estimated)
Target follow-up
1 Day
Patient registry
Yes

Groups and cohorts

  • Acute copd patients

    acute exacerbation of COPD

  • stable copd patients

    clinically stable without any acute exacerbations for at least the past 4 weeks.

06

What researchers measure

Primary outcomes

  1. Muscle Oxygen Saturation

    Muscle oxygen saturation (SmO\_2) will be measured continuously using Near-Infrared Spectroscopy (NIRS) (Train.Red FYER) on the intercostal, deltoid, and dominant quadriceps muscles. The primary parameter ΔSmO\_2 max represents the difference between the peak SmO\_2 during functional tasks (30-second sit-to-stand test, 4-meter gait speed test, and upper extremity assessment) and the baseline resting

    Time frame: baseline (1 day)

Secondary outcomes

  1. functional capacity

    30-Second Sit-to-Stand Test: Assesses functional lower-limb muscle strength and exercise capacity. The total number of completed full stand-ups from a chair (height 43.2 cm) within 30 seconds will be recorded.

    Time frame: baseline (1 day)

  2. Gait speed

    4-Meter Gait Speed Test: Gait speed will be evaluated over a 4-meter course at normal walking pace. Gait speed is calculated in meters per second (m/s) by dividing 4 meters by the time taken

    Time frame: baseline (1 day)

  3. Peripheral Muscle Strength

    Maximal isometric handgrip strength will be measured in kilograms (kg) using a digital hand dynamometer (Baseline BIMS). The highest value of three trials for both dominant and non-dominant hands will be recorded

    Time frame: baseline (1 day)

  4. pulmonary functions

    Spirometry will be performed according to ATS/ERS guidelines. Values will be recorded.

    Time frame: baseline (1 day)

  5. Dyspnea and Fatigue Perception

    Dyspnea will be evaluated using the Modified Medical Research Council (mMRC) scale (grades 0-4) and Visual Analog Scale (VAS, 0-10 cm). Fatigue perception will be assessed using the Modified Borg Scale (0-10) before and after functional tests.

    Time frame: baseline (1 day)

  6. Activities of Daily Living

    Activities of daily living will be assessed using the London Chest Activity of Daily Living (LCADL) scale (score range 0-75).

    Time frame: baseline (1 day)

07

Study locations

1 site
  • Hacettepe University
    Ankara, Turkey (Türkiye)
    • Aynur Demirel, PT, PhD, Assoc. Prof. · Contactaynur.demirel@hacettepe.edu.tr · +905545295057
    • Alper Kemal Gurbuz, PT, MSc. · Sub investigator
    • Irem Suzen, PT, MSc. · Sub investigator
    • Hidaye Yamikan, PT, MSc. · Sub investigator
    • Gulse Ozer, PT · Sub investigator
    • Aysu Yalman, PT, MSc. · Sub investigator
    • Oguz Karcioglu, MD, Assoc Prof. · Sub investigator
    • Aynur Demirel, PT, PhD, Assoc. Prof. · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2026; primary completion for Oct 2027, 13 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2026
First posted
Sep 3, 2026
StartEst.
Aug 30, 2026
Primary completionEst.
Oct 5, 2027
CompletionEst.
Feb 5, 2028
Last update
Sep 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07801547
Responsible party
Aynur Demirel (PT, PhD, Assoc. Prof., Hacettepe University) — Principal investigator
First posted
Sep 3, 2026
Start date
Aug 30, 2026 (estimated)
Primary completion
Oct 5, 2027 (estimated)
Completion
Feb 5, 2028 (estimated)
Last update
Sep 3, 2026

Study contacts

Aynur Demirel, PT, PhD, Assoc. Prof.
Contact
aynur.demirel@hacettepe.edu.tr
+90 554 529 5057
Alper kemal Gurbuz, PT, MSc.
Contact
Aynur Demirel
study director · Hacettepe University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion